Pakistan is set to introduce HPV vaccine for first time to prevent Cervical Cancer...

Blog - In an historic moment for regional solidarity and leadership, West African Ministers of Health today pledged their joint commitment to advance the development of, and readiness for, much-needed vaccines against Lassa fever in recognition of the significant threat to regional health security...

Russia’s first personalized melanoma vaccines are poised for production, with patient treatment expected soon following promising preclinical results.

Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode,Drs Elizabeth Bukusi, Peter Godfrey-Faussett, and Nina Russell discuss promising advances in the field of HIV vaccine research and how we can prepare for optimal rollout of an eventual HIV vaccine. Presenters: Elizabeth Anne Bukusi, MBChB, M.Med (ObGyn), MPH, PhD , PGD (Research Ethics), MBE (Research Ethics), CIP Senior Principal Clinical Research Scientist Center for Microbiology Research KEMRI Research Professor Departments of Global Health and Obstetrics and Gynecology University of Washington, Nairobi, Kenya Seattle, Washington Peter Godfrey-Faussett, MBBS, FRCP(UK) Science Advisor United Nations Joint Programme on HIV (UNAIDS) Professor of Infectious Diseases and International Health London School of Hygiene and Tropical Medicine London, United Kingdom Nina Russell, MD Director for TB and HIV Prevention Bill & Melinda Gates Foundation Seattle, Washington Link to full series: https://bit.ly/2UgrQ12 Link to the HIV unmuted series from IAS: https://hivunmuted.iasociety.org/ Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Swati Gupta and Mr. Marc Dixneuf discuss how to broaden global advocacy and increase investment for an HIV vaccine. Presenters: Swati Gupta, DrPH, MPH Vice President and Head of Emerging Infectious Diseases and Scientific Strategy International AIDS Vaccine Initiative New York, New York Marc Dixneuf, PhD Director General AIDES Pantin, France Special Commentator: Jonathan Weber, MB, BChir, PhD, FRCP, FRCPath, FMed Sci Dean of the Faculty of Medicine Imperial College London, United Kingdom Link to full series: https://bit.ly/3ytytMY Link to the HIV unmuted series from IAS: https://bit.ly/3f5qC0d Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Susan Buchbinder and Mr. Jontraye Davis discuss what has been learned and built through the past 40 years of HIV vaccine research, including how HIV vaccine scientific advancements and infrastructure were critical to the success of developing a COVID-19 vaccine. Presenters: Susan Buchbinder, MD Clinical Professor Departments of Medicine, Epidemiology and Biostatistics University of California, San Francisco Director, Bridge HIV San Francisco Department of Public Health San Francisco, California Jontraye Davis, MHA, PMD Pro Community Program Manager FHI 360 Adjunct Instructor North Carolina Central University Durham, North Carolina Special Commentator: Jerome H. Kim, MD Director General International Vaccine Institute Seoul, South Korea Link to full series: https://bit.ly/3ytytMY Link to the HIV unmuted series from IAS: https://bit.ly/3f5qC0d Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this first episode, Dr. Linda-Gail Bekker and Ms. Maureen Luba discuss why an HIV vaccine remains the ultimate game-changer to ending the epidemic and the gaps it will address in the expanding HIV prevention landscape. Presenters: Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Chief Operating Officer Desmond Tutu HIV Foundation Deputy Director Desmond Tutu HIV Centre Past President International AIDS Society Faculty of Health Sciences University of Cape Town Cape Town, South Africa Maureen Luba Africa Region Advocacy Advisor Global Advocacy for HIV Prevention AIDS Vaccine Advocacy Coalition Link to full series: https://bit.ly/3ytytMY Link to the HIV unmuted series from IAS: https://bit.ly/3f5qC0d Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Broad-spectrum vaccines have been proposed as a tool for rapid response to emerging infectious disease threats and are in pre-clinical development. Here, the authors use mathematical modelling to assess the potential impacts of broadly protective sarbecovirus vaccines for a hypothetical “SARS-X”...

Vaccines provide one of the most reliable defenses against infectious diseases. By stimulating the body’s immune system to recognize and fight off harmful pathogens, they create a protective barrier long before exposure occurs.

UEFA and Gavi are working together to harness the power of football to raise awareness about vaccines in Africa.

People who whistle past the graveyard (of vaccines) to assure themselves the RFK Jr,. won't take away their vaccines are deluding themselves. It's on video!

Containing work by artists including Chris Foss, Ian Miller, David Pelham, Bruce Pennington, David A. Hardy, Tim White, Bob Fowke, and Roger Dean, the Science Fiction Monthly poster magazine was publi...